Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Front Cell Dev Biol ; 11: 1176083, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37389354

RESUMEN

Advanced non-small cell lung cancer (NSCLC) with MET amplification primarily relies on MET inhibitors for treatment, but once resistance occurs, the available treatment options are limited and the prognosis is typically poor. A 57-year-old man with advanced NSCLC and C-MET amplification was initially treated with crizotinib but developed progressive disease. After the antirotinib treatment, he achieved a partial response for a year. Genetic testing showed high PD-L1 expression, and he was treated with pembrolizumab and chemotherapy for 3 months, with partial response. Maintenance therapy with pembrolizumab and local I-125 seeds brachytherapy (ISB) was given after the lung lesion progressed but other lesions remained stable. The therapy resulted in significant resolution of the right upper lung lesion. It demonstrates the effectiveness of ISB-ICI combination in treating MET amplification advanced NSCLC. Ongoing research and treatment innovation are important in managing advanced NSCLC with complex genetic aberrations. To explore the candidate mechanism of ISB therapy response, we download public genetic data and conduct different expression Lncrnas analysis and pathway analysis to discover radiotherapy related sensitive or resistance lncRNAs and pathways, we found that AL654754.1 is a key lncRNA with radiotherapy response, and it also include in classical p53 and Wnt signaling pathway. Overall, the clinical case reports, combined with the exploration of underlying mechanisms, provide positive guidance for the precise treatment of lung cancer.

2.
Biotechnol Lett ; 37(12): 2467-74, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26315606

RESUMEN

OBJECTIVE: To increase the resistance of ingested bacteria to multiple environmental stresses, the role of transglutaminase in Lactococcus lactis and possible mechanisms of action were explored. RESULTS: L. lactis grown with transglutaminase exhibited significantly higher resistance to bile salts, stimulated gastric juice, antibiotics, NaCl, and cold stress compared to the control (cultured without transglutaminase), with no negative influence on cell growth. Transmission electron microscopy revealed that the cell walls of L. lactis cultured with 9 U transglutaminase/ml were approx. 1.9-times thicker than the control. Further analysis demonstrated that the multi-resistant phenotype was strain-specific; that is, it occurred in bacteria with the presence of glutamine and lysine in the peptidoglycan. CONCLUSION: Supplementation of culture media with transglutaminase is an effective, simple, and inexpensive strategy to protect specific ingested bacteria against multiple environmental challenges.


Asunto(s)
Pared Celular/química , Glutamina/análisis , Lactococcus lactis/efectos de los fármacos , Limosilactobacillus fermentum/efectos de los fármacos , Lisina/análisis , Estrés Fisiológico , Transglutaminasas/metabolismo , Antibacterianos/metabolismo , Pared Celular/ultraestructura , Frío , Limosilactobacillus fermentum/fisiología , Limosilactobacillus fermentum/ultraestructura , Lactococcus lactis/fisiología , Lactococcus lactis/ultraestructura , Microscopía Electrónica de Transmisión , Peptidoglicano/análisis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...